

POWER OF ATTORNEY FROM ASSIGNEE WITH DELEGATION

Biotie Therapies Corp., a corporation of Finland, having a principal place of business at Tykistökatu 6, FIN-20520 Turku, FINLAND, is assignee of the entire right, title, and interest for the United States of America (as defined in 35 U.S.C. §100), by reason of an Assignment to the Assignee executed on (1) 15 October 2001
(2) 4 October 2001
(3) 15 October 2001
(4) 5 October 2001
(5) 17 Oct 2001
(6) 18 October 2001
(7) 8 October 2001 of an invention known as Carbocyclic Hydrazino Inhibitors of Copper-Containing Amine Oxidases (Attorney Docket No. 1708.010000/JMC/AES), which is disclosed and claimed in a patent application of the same title by the inventors (1) David John SMITH; (2) Ferenc FÜLÖP; (3) Mario PIHLAVISTO; (4) László LÁZÁR; (5) Sakari ALARANTA; (6) Petri VAINIO; and (7) Zsolt SZAKONYI (said application filed on July 12, 2001 at the U.S. Patent and Trademark Office, having Application Number 09/902,789).


The Assignee hereby appoint the U.S. attorneys associated with **CUSTOMER NUMBER 28393** to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith, such attorneys currently being: Robert Greene Sterne, Registration No. 28,912; Edward J. Kessler, Registration No. 25,688; Jorge A. Goldstein, Registration No. 29,021; David K.S. Cornwell, Registration No. 31,944; Robert W. Esmond, Registration No. 32,893; Tracy-Gene G. Durkin, Registration No. 32,831; Michele A. Cimbala, Registration No. 33,851; Michael B. Ray, Registration No. 33,997; Robert E. Sokohl, Registration No. 36,013; Eric K. Steffe, Registration No. 36,688; Michael Q. Lee, Registration No. 35,239; Steven R. Ludwig, Registration No. 36,203; John M. Covert, Registration No. 38,759; and Linda E. Alcorn, Registration No. 39,588. The Assignee hereby grants said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

The Assignee hereby authorizes the U.S. attorneys named herein to accept and follow instructions from Kolster Oy Ab, Iso Roobertinkatu 23, FIN-00121, Helsinki, FINLAND as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and the Assignee. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by the Assignee.

Send correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
U.S.A.

Direct phone calls to 202-371-2600.

FOR: BioTie Therapies Corp.
SIGNATURE: 
BY: Markku Jalkanen
TITLE: CEO
DATE: 5.3.2002

RECEIVED
MAR 26 2002
TECH CENTER
JCB8